Vol. I · No. 33
Thursday, August 13, 2026
Issue: Summer · 2026
Established · MMXXVI
— The evidence base for longevity medicine —
Indexed by PubMed · CTG · Cochrane
Editorial team · geroevidence.com
Subscription · app.geroevidence.com

Low-dose lithium and longevity: epidemiology, mechanism, and the evidence gap

Epidemiological studies link lithium in drinking water to lower dementia rates and longer lifespan. The human supplementation evidence is sparse.

By Geroevidence editorial team·Published 19 July 2026·Category intervention profiles·10 min read
Emerging
Evidence tier
Mood stabilizer / neuroprotective
Drug class
Human RCTs
Evidence base
§ Overview

Epidemiological studies link lithium in drinking water to lower dementia rates and longer lifespan. The human supplementation evidence is sparse.

This profile synthesizes the published human evidence. The evidence tier system — Strong, Moderate, Emerging, Insufficient — is based on published peer-reviewed data only, with hard longevity outcomes weighted more heavily than surrogate endpoints. The full profile with all indexed papers and active trial alerts is available to subscribers.

§ Key human evidence
Ecological study
Nunes et al. — British Journal of Psychiatry, 2007
n=>500,000
Texas drinking water data. Counties with higher natural lithium levels in water had significantly lower suicide rates. One of the founding studies in this literature. Ecological study: confounding by many unmeasured county-level variables is possible.
Ecological study
Fajardo et al. — European Journal of Nutrition, 2018
n=18 European countries
Cross-national analysis. Higher tap water lithium concentrations associated with lower all-cause mortality and lower Alzheimer's disease mortality. Key limitation: ecological fallacy — country-level associations do not establish individual-level causation.
RCT
Nunes et al. — British Journal of Psychiatry, 2013
n=45
Older adults with mild cognitive impairment. 150mcg/d lithium (microdose) for 15 months versus placebo. Cognitive decline halted in lithium arm — MMSE improved slightly while placebo group declined. Small trial. Key study for low-dose supplementation concept. Not replicated at scale.
§ The honest clinical position

Evidence tier: Emerging. The case for clinical consideration rests on the mechanistic coherence and the published surrogate-endpoint human trial signal. The case for caution rests on the absence of hard longevity outcome data in adequately powered trials.

A physician discussing this intervention with a patient should communicate the evidence tier honestly and distinguish between what has been shown in published trials versus what is claimed in supplement marketing. The full Geroevidence profile includes the specific papers, effect sizes, and confidence intervals that inform this assessment.

This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.

Full evidence profile
All indexed papers · active trials · daily alerts
Start free trial
14 DAYS FREE · NO CARD REQUIRED
Top interventions by evidence tier
GLP-1 agonists
Cardiovascular outcome trials
Strong
Rapamycin
mTOR inhibitor · PEARL trial
Moderate
Metformin
AMPK activator · TAME pending
Moderate
View full index →